Matrix metalloproteinases and their inhibitors in human traumatic spinal cord injury by Buss, Armin et al.
BioMed CentralBMC Neurology
ssOpen AcceResearch article
Matrix metalloproteinases and their inhibitors in human traumatic 
spinal cord injury
Armin Buss*1, Katrin Pech1, Byron A Kakulas2, Didier Martin3, 
Jean Schoenen4, Johannes Noth1 and Gary A Brook1,5
Address: 1Department of Neurology, Aachen University Hospital, Aachen, Germany, 2Centre for Neuromuscular and Neurological Disorders, 
University of Western Australia, Perth, Australia, 3Department of Neurosurgery, Sart Tilman Hospital, University of Liège, Liège, Belgium, 
4Departments of Neurology and Neuropathology, University of Liège, Liège, Belgium and 5Department of Neuropathology, Aachen University 
Hospital, Aachen, Germany
Email: Armin Buss* - abuss@ukaachen.de; Katrin Pech - pech13@gmx.de; Byron A Kakulas - bkakulas@cyllene.uwa.edu.au; 
Didier Martin - didier.martin@chu.ulg.ac.be; Jean Schoenen - jschoenen@ulg.ac.be; Johannes Noth - jnoth@ukaachen.de; 
Gary A Brook - gary.brook@rwth-aachen.de
* Corresponding author    
Abstract
Background: Matrix metalloproteinases (MMPs) are a family of extracellular endopeptidases that degrade the
extracellular matrix and other extracellular proteins. Studies in experimental animals demonstrate that MMPs play
a number of roles in the detrimental as well as in the beneficial events after spinal cord injury (SCI). In the present
correlative investigation, the expression pattern of several MMPs and their inhibitors has been investigated in the
human spinal cord.
Methods: An immunohistochemical investigation in post mortem samples of control and lesioned human spinal
cords was performed. All patients with traumatic SCI had been clinically diagnosed as having "complete" injuries
and presented lesions of the maceration type.
Results: In the unlesioned human spinal cord, MMP and TIMP immunoreactivity was scarce. After traumatic SCI,
a lesion-induced bi-phasic pattern of raised MMP-1 levels could be found with an early up-regulation in
macrophages within the lesion epicentre and a later induction in peri-lesional activated astrocytes. There was an
early and brief induction of MMP-2 at the lesion core in macrophages. MMP-9 and -12 expression peaked at 24
days after injury and both molecules were mostly expressed in macrophages at the lesion epicentre. Whereas
MMP-9 levels rose progressively from 1 week to 3 weeks, there was an isolated peak of MMP-12 expression at
24 days. The post-traumatic distribution of the MMP inhibitors TIMP-1, -2 and -3 was limited. Only occasional
TIMP immuno-positive macrophages could be detected at short survival times. The only clear induction was
detected for TIMP-3 at survival times of 8 months and 1 year in peri-lesional activated astrocytes.
Conclusion: The involvement of MMP-1, -2, -9 and -12 has been demonstrated in the post-traumatic events after
human SCI. With an expression pattern corresponding largely to prior experimental studies, they were mainly
expressed during the first weeks after injury and were most likely involved in the destructive inflammatory events
of protein breakdown and phagocytosis carried out by infiltrating neutrophils and macrophages, as well as being
involved in enhanced permeability of the blood spinal cord barrier. Similar to animal investigations, the strong
induction of MMPs was not accompanied by an expression of their inhibitors, allowing these proteins to exert
their effects in the lesioned spinal cord.
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After traumatic spinal cord injury (SCI), the initial dam-
age to the parenchyma at the lesion site is followed by a
complex cascade of secondary events including break-
down of the blood spinal cord barrier (BSB) and infiltra-
tion of blood-derived inflammatory cells, oedema,
excitotoxicity and ischemia. Experimental investigations
have revealed that this phase of secondary parenchymal
damage spans the first 48–72 hours post injury and is fol-
lowed by the removal of tissue debris over subsequent
weeks. Finally, the lesion site of severely injured tissue
becomes dominated by scar tissue comprised of connec-
tive tissue, including Schwann cells and meningeal fibrob-
lasts, and fluid-filled cysts, surrounded by a dense
astroglial scar [1]. Remodelling of the extracellular matrix
(ECM) plays an important role in most of these events
Matrix metalloproteinases (MMPs) are a family of extra-
cellular zinc- and calcium-dependent endopeptidases that
degrade the extracellular matrix and other extracellular
proteins [2]. The 23 mammalian MMPs can be placed into
sub-groups based on structural similarities and substrate
specificity and they are capable of degrading virtually all
extracellular proteins. Once activated, MMPs are subject
to inhibition by 4 different tissue inhibitors of metallo-
proteinases (TIMPs) that bind MMPs non-covalently [3].
MMPs are involved in events requiring matrix remodel-
ling in developmental processes, wound healing and
repair throughout life. In the nervous system, these
enzymes play a role in the migration of precursor cells to
their destination and are directly involved in axonal out-
growth during development [4]. However, the aberrant
expression of members of this protein family is involved
in disease processes such as cancer metastasis and CNS
disorders including multiple sclerosis, stroke, Alzheimer's
disease and trauma [4,5]. Recent experimental SCI inves-
tigations have demonstrated an involvement of MMPs in
the post-traumatic events. In a mouse spinal cord com-
pression injury model, a significant up-regulation of 11
MMPs was demonstrated [6]. Most of the proteins, includ-
ing MMP-3, -9 and -10, showed an early induction, start-
ing 24 hours after injury whereas the expression of other
MMPs, including MMP-2, -12 and -13, was delayed until
5 days after trauma. Further studies into the role of MMP-
12, the most markedly up-regulated MMP, demonstrated
improved recovery in MMP-12 null mice, most likely due
to a reduction of the lesion-induced permeability of the
blood spinal cord barrier (BSB) and a reduced density of
microglia/macrophages at the lesion site [6]. An investiga-
tion into the role of MMP-9 in SCI showed similar results
in a contusion injury model, with improved locomotor
function in MMP-9 null mice as compared to wild-type
animals. Again, a reduction of the lesion-induced perme-
ability of the BSB and a resulting attenuation of inflam-
matory cell infiltration were suggested to be the likely
mechanisms for the favourable outcome [7]. Another
study in mice undergoing a spinal cord contusion injury
correlated the up-regulation of MMP-2 mainly to the for-
mation of the glial scar [8]. In MMP-2 null mice, there was
reduced white matter sparing, less nerve fibre regeneration
and a more extensive astroglial scarring compared to their
wild type littermates. These results suggest that MMP-2
up-regulation promotes functional recovery after SCI by
regulating glial scar formation and white matter sparing.
Therefore, studies in experimental animals have demon-
strated that MMPs play a number of roles in the detrimen-
tal, early inflammation-related processes as well as in the
later, beneficial wound healing and regenerative events
[4,5]. In the present investigation, the expression pattern
of several MMPs and their inhibitors has been investi-
gated in samples of post mortem human spinal cord, taken
from 15 patients who died at a range of survival times fol-
lowing traumatic SCI. Our data reveals an induction of
MMPs-1, -2, -9 and -12 with an individual profile for each
protein. The present data demonstrates a strong correla-
tion with some aspects of the data obtained from experi-
mental animals. However, some clear differences appear
to exist between animal and human tissues following spi-
nal cord injury.
Methods
Post mortem, the spinal cords were removed from 4 control
patients who had not suffered from any neurological dis-
ease (Table 1) and from 15 patients who died at a range of
time points after traumatic spinal cord injury (Table 2).
The study was approved by the Aachen University Ethics
Committee. Patients with traumatic injury had been diag-
nosed as having "complete" injuries and presented with
paraplegia or tetraplegia. The spinal columns of both con-
trol and SCI patients were removed at autopsy, approxi-
mately 15–48 hours after death. Following incision of the
dura mater, the spinal cord was fixed in 4% buffered for-
maldehyde for at least 2 weeks. Thereafter, blocks of the
lesion site and/or tissue from regions rostral and caudal to
the lesion (approximately 1 cm thickness) were embed-
ded in paraffin wax.
Peroxidase immunohistochemistry
Transverse sections (5 µm thick) were collected onto poly-
L-lysine-coated slides and allowed to dry. Sections were
Table 1: Patients who served as the control group
Case number Age Cause of death
1 29 years Breast cancer
2 47 years Pneumonia
3 62 years Breast cancer
4 83 years Myocardial infarctionPage 2 of 12
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in 10 mM citrate buffer (pH 6) for 3 × 3 minutes was fol-
lowed by blockade of non-specific binding by incubation
in 0.1 M PBS containing either 3% normal horse or nor-
mal goat serum and 0.5% triton X-100 for 30 minutes.
Sections were subsequently incubated in the following
primary antibodies, overnight at room temperature:
mouse monoclonal anti-MMP-1 (1:4000; Chemicon),
mouse monoclonal anti-MMP-2 (1:20; Calbiochem),
mouse monoclonal anti-MMP-9 (1:100; R&D Systems),
mouse monoclonal anti-MMP-12 (1:10; R&D Systems),
mouse monoclonal anti-TIMP-1 (1:300; Chemicon), rab-
bit polyclonal anti-TIMP-2 (1:250; Chemicon), mouse
monoclonal anti-TIMP-3 (1:100; Chemicon), rabbit poly-
clonal anti-glial fibrillary acidic protein (1:2500, DAKO)
and mouse monoclonal anti-CD68 (1:50; DAKO). Fol-
lowing extensive rinsing steps in 0.1 M PBS, sections were
incubated in biotinylated horse anti-mouse or goat anti-
rabbit antibody (diluted 1:500, Vector Laboratories) for 1
hour at room temperature. Incubation with the bioti-
nylated secondary antibody was followed by the Vector
ABC system and a subsequent incubation in diaminoben-
zidine for visualization of the reaction product. For nega-
tive controls the primary antibody was omitted. Those
sections incubated with the CD68 antibody were finally
counterstained with 0.2% thionin for 1 minute.
Immunofluorescence
Sections were de-waxed in xylene and rehydrated. Micro-
wave treatment in 10 mM citrate buffer (pH 6) for 3 × 3
minutes was followed by blockade of non-specific bind-
ing by incubation in 3% normal goat serum in 0.5% triton
X-100 in 0.1 M PBS for 30 minutes and subsequent incu-
bation overnight at room temperature with the anti-MMP-
1 antibody (1:250) or the anti-TIMP-3 antibody (1:20)
and the anti-GFAP antibody (1:200). Following incuba-
tion with Alexa 594 (red-fluorescence)-conjugated goat
anti-mouse and Alexa 488 (green fluorescence)-conju-
gated goat anti-rabbit secondary antibodies (diluted
1:500, Molecular Probes) for 3 hours at room tempera-
ture, slides were cover-slipped in Moviol.
For MMP and CD68 double staining, the tyramide signal
amplification kit (TSA Cyanine 3 system, NEL704A, Perk-
inElmer Life Sciences) was used. Briefly, following the
blockade of endogenous tissue peroxidase, sections were
rinsed in the TSA block buffer (prepared as recommended
by the manufacturers) and incubated with the anti-MMP-
1, -2, -9 or -12 antibodies at a dilution of 1:200 overnight.
Incubation with a biotinylated horse anti-mouse anti-
body (1:500, BA2000, Vector) for 1 hour, rinsing in
0.05% Tween20 and blocking with the provided reagent
for 30 minutes was followed by streptavidin-HRP (1:500)
in blocking reagent for 30 minutes and Cyanine 3-tyra-
mide working solution (1:100) for 10 minutes. After rins-
ing, the slides were incubated with the monoclonal anti-
CD68 primary antibody (1:30) overnight, followed by a
Cy2-conjugated goat anti-mouse antibody (1:100, Jack-
son Laboratories) for 3 hours at room temperature.
Finally, nuclei were stained for 5 minutes with DAPI
(diluted 1:1000, Sigma) and the sections were cover-
slipped with Moviol. For negative controls, the primary
antibodies were omitted.
For a semi-quantitative description of the amount of
MMP-immunoreactive cells at the various survival times,
an arbitrary rating scale for the number of labelled cells
was chosen, ranging from 0 to ++++. A value of 0 indi-
cated the detection of no immunopositive cells while a
value of ++++ indicated the presence of large numbers of
labelled cells.
Results
Samples of spinal cord from all 19 cases were examined
using immunohistochemistry for MMP-1, -2, -9 and -12,
TIMP-1, -2 and -3 as well as CD68 and GFAP. The brains
of all cases were carefully examined and were declared to
be without pathological findings. The spinal cords of the
control cases were also morphologically intact. For an
overview of the results, especially the number of immuno-
reactive cells at the lesion epicentre at the various survival
times, see table 3. The interpretation of the semi-quantita-
tive presentation of MMP and TIMP expression is
restricted, due to the limited comparability of staining
quality (largely due to differences in the time between
death and the dissection/fixation of tissue). However,
immunohistochemistry was performed using the identi-
cal staining procedure and cases with closely matching
survival times (e.g. 4–5 days and 10–11 days after SCI)
demonstrated very similar amounts of MMP and TIMP
immunoreactivity.
Table 2: Patients who died after traumatic injury to the spinal 
cord
Case number Age Injury level Inj.-death interval
1 21 years T12 2 days
2 51 years C1 4 days
3 84 years C3-4 5 days
4 65 years C5 8 days
5 63 years C6 10 days
6 18 years T6 11 days
7 72 years T11-12 24 days
8 85 years C3 4 months
9 76 years T8-9 10 months
10 80 years C5-6 1 year
11 72 years T12 2 years
12 44 years L1 8 years
13 71 years C3-4 20 years
14 47 years T5 26 years
15 57 years T3-4 30 yearsPage 3 of 12
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spinal cord
The spinal cord parenchyma including the meninges was
immunonegative for MMP-2 and -12 and TIMP-1 (not
shown). Immunohistochemistry for MMP-1 revealed
staining in most motoneurons and Clarke's nucleus neu-
rons as well as scattered interneurons, mostly in laminae
IV to VI (Fig.1A). Staining for MMP-9 demonstrated rare
intravascular monocytes in both meningeal and paren-
chymal blood vessels (Fig.1B). TIMP-2 immunoreactivity
was present in most motoneurons and individual Clarke's
nucleus neurons and interneurons from laminae I to VI
(Fig.1C). TIMP-3 revealed a similar distribution but with
only approximately 50% of motoneurons stained in cervi-
cal, thoracic and lumbar segments (Fig.1D). This distribu-
tion was detected in all 4 control cases, and no evidence
for age-related changes in the distribution of MMP and
TIMP isoforms could be found in any of the normal
human CNS samples.
Macrophage/microglial responses to human SCI
In the normal unlesioned spinal cord, CD68 immunore-
activity was scarce. Occasional bipolar perivascular cells
(e.g. arrowheads, Fig.2A) and intravascular monocytes
were immunopositive. Although sections from the lesion
site demonstrated no preservation of cytoarchitecture at 2
days after SCI, there was a slight increase in the incidence
of CD68-positive cells. These cells were round to oval-
shaped and were spread over the lesion core and the peri-
lesional area (Fig.2B–C). By 4 and 5 days after injury, the
number of immunopositive cells at the lesion epicentre
was further increased. Microglia/macrophages could be
found in the area of necrosis, either as individual cells or
as small clusters (Fig.2D). In peri-lesional gray matter
areas, reactive CD68-positive microglia/macrophages
were sometimes found in close apposition to neuronal
cell bodies (Fig.2E). By 8, 10, 11 and 24 days post injury,
the lesion core contained numerous microglia/macro-
phages, mostly with the morphology of foamy macro-
phages (Fig.2F and 2G) but by 4 months, fewer CD68
immunoreactive cells could be detected at the lesion site
(Fig.2H). Sections from tissue blocks of all later survival
times demonstrated a few remaining immunoreactive
cells with a peri-vascular distribution, similar to that seen
in the control cases (not shown).
Astrocytic reaction to human SCI
GFAP immunohistochemistry in the normal, unlesioned
spinal cord revealed astrocytic cell bodies evenly dispersed
throughout spinal cord gray and white matter, scattered
between the network of astrocytic processes (Fig.3A). At
Distribution of MMPs and TIMPs in the normal human spinal cordFigure 1
Distribution of MMPs and TIMPs in the normal 
human spinal cord. Images were taken from control 
human spinal cords in transverse sections. A: Immunohisto-
chemistry for MMP-1 revealed cytoplasmic staining in 
motoneurons; the nucleus was devoid of immunoreactivity. 
B: Staining for MMP-9 demonstrated a single intravascular 
monocyte (arrow) within a parenchymal blood vessel. C: 
The TIMP-2 antibody displayed cytoplasmic immunoreactivity 
in motoneurons, the nucleus being devoid of staining. D: 
Immunohistochemistry for TIMP-3 also shows cytoplasmic 
staining in motoneurons without a nuclear signal. (A-D, 
mag. ×260)
Table 3: Amount of immunopositive cells at the lesion epicentre at different survival times following human SCI
Control 2 days 4–5 days 8 days 10–11 days 24 days 4 months
CD68 0/+ + +++ ++++ ++++ ++++ ++
MMP-1 + + ++ +++ + + + (astrocytes)
MMP-2 0 + ++ +++ ++ + 0
MMP-9 0/+ + ++ +++ +++ +++ 0/+
MMP-12 0 + + + + ++++ 0
TIMP-1 0 0/+ 0/+ 0/+ 0/+ 0/+ 0
TIMP-2 + 0/+ 0/+ 0/+ 0/+ 0/+ +
TIMP-3 0/+ 0/+ 0/+ 0/+ 0/+ 0/+ 0/+
The figures reflect the number of immunopositive cells using an arbitrary rating scale from 0 (no cells) to ++++ (maximum amount of cells) in 
sections from control spinal cords and the lesion core at various survival times after SCI stained for the different antigens.Page 4 of 12
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the areas of massive tissue destruction demonstrated a
massive reduction of GFAP immunoreactivity. Hardly any
astroglial cell bodies and an irregular, loose arrangement
of processes were detectable (Fig.3B). In cases with sur-
vival times of 4 days and longer, perilesional, highly
GFAP-positive, activated astrocytes could be seen. These
cells were distributed homogeneously over white and gray
matter in sections up to 1 to 2 segments proximal and dis-
tal to the lesion site (Fig.3C). By eleven days, nests of
large, intensely GFAP-positive astrocytes surrounded by a
dense irregular network of processes could be observed
(Fig.3D). The formation of the glial scar progressed, and
in cases with survival times of 4 months and longer, a
dense astroglial, GFAP-positive, scar was visible in which
the cell bodies were hardly detectable (Fig.3E). In the peri-
lesional areas up to 1 segment away from the lesion site,
activated astroglia could still be detected up to 1 year after
trauma (Fig.3F).
Expression of MMP-1 after human SCI
At all survival times, the neuronal distribution of MMP-1
in the peri-lesional area remained unchanged (Fig.4A and
4F). At 2 days, some round to oval cells were seen at the
site of injury. They were detectable in the heavily
destroyed tissue but were present at a lower density than
the CD68- positive macrophages/microglia. Four days
after trauma, immunoreactive cells, morphologically
resembling macrophages, could be seen in areas of bleed-
ing and massive tissue destruction (Fig. 4B) and by 8 days,
the lesion core contained substantial numbers of immu-
noreactive cells, corresponding in size, distribution and
morphology to the CD68 (and MMP-9, see below)-posi-
tive cells observed in near adjacent sections (Fig.4C and
7A). By 10–24 days, the incidence of MMP-1 positive cells
was dramatically decreased and only single round cells
were detectable (Fig.4D). However, sections taken from
the peri-lesional area between 4 months and 1 year post
injury revealed large, MMP-1 positive cell bodies which
were subsequently demonstrated to be astrocytes by dou-
ble immunofluorescence (Fig.4E and 7B).
Expression of MMP-2 after human SCI
Immunohistochemistry for MMP-2 demonstrated the first
positive cells in sections from the lesion epicentre at 2
days after injury. In areas of massive destruction and hem-
orrhagic infiltration, a few positive round cells were
detected whereas areas of the lesion site without bleeding
demonstrated a higher number of immunoreactive cells
with a round to oval morphology (Fig.5A–B). By 8 days,
the morphology and distribution of the cells within the
lesion site corresponded to those of CD68-positive mac-
rophages (Fig.5C–D). However, by 10 days the number of
MMP-2 positive macrophages was clearly reduced
(Fig.7C) and by 24 days, only single immunoreactive cells
Macrophages/microglia in the human spinal cord after trau-matic injuryFigure 2
Macrophages/microglia in the human spinal cord after 
traumatic injury. Images were taken from control spinal 
cords and cases with different survival times after SCI in 
transverse sections stained with the CD68 antibody. A: In a 
control spinal cord, CD68 immunohistochemistry reveals 
bipolar peri-vascular cells (arrow). B: Two days after SCI, sec-
tions from the lesion site demonstrated a clear up-regulation 
of CD68-positive cells. Round to oval shaped cells (arrows) 
were spread over the area. C: In the same case, areas of 
bleeding contained some round immunopositive macrophages 
(arrows). The diffuse brown background staining was unspe-
cific, being due to the high concentration of endogenous per-
oxidase in the blood cells. D: 4 days after injury, the lesion 
area displayed an increased number of CD68-positive cells, 
many with activated microglial and rounded macrophage-like 
morphologies. E: In the peri-lesional gray matter of the same 
case, identifiable neurons (arrowheads) were often closely 
surrounded by CD68 positive cells. F: 10 days after injury, the 
lesion epicentre was filled with numerous microglia/macro-
phages. G: 24 days after injury, the lesion epicentre was heav-
ily loaded with large, foamy macrophages. H: Four months 
after SCI, only few immunoreactive cells can be seen at the 
site of injury. (A-H, mag. ×260)Page 5 of 12
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staining was visible, similar to control cases (not shown).
Expression of MMP-9 after human SCI
By 2 days after injury (the earliest time point investigated)
staining for MMP-9 demonstrated immunoreactive cells
at and around the lesion site. In areas of severe tissue
destruction and intensive bleeding, only few cells with a
round morphology were stained (Fig.5E). At 4–5 days
after injury, in areas at the lesion epicentre but without
signs of hemorrhagic infiltration, the amount of immuno-
reactive cells was higher compared to other heavily
destroyed areas. The cells were mostly of a round mor-
phology and were relatively evenly distributed except for
clusters of positive cells in and around blood vessels
(Fig.5F). Double immunofluorescence with an anti-CD68
antibody demonstrated a microglia/macrophage origin of
most MMP-9 positive cells (Fig.7D). Morphologically, the
MMP-9 positive/CD68-negative cells at these early sur-
vival times resembled infiltrating neutrophils. In sections
MMP-1 in the human spinal cord after traumatic injuryFigure 4
MMP-1 in the human spinal cord after traumatic 
injury. Images were taken from cases with different survival 
times after SCI in transverse sections stained with the MMP-
1 antibody. A: Two days after injury, motoneurons in the 
perilesional area retained their cytoplasmic MMP-1 immuno-
reactivity. B: Four days after SCI, MMP-1 immunohistochem-
istry at the site of injury displayed round to oval cells 
(arrowheads). C: By 8 days, the lesion site was filled with a 
high number of MMP-1 immunoreactive cells. Again, more 
round to oval shaped cells can be seen. D: At 11 days after 
SCI, the amount of MMP-1 stained cells was dramatically 
decreased and only single round cells were detectable. E: 4 
months after injury, large MMP-1 positive cells could be seen 
around the site of injury with the morphology of activated 
astrocytes. F: 8 months after SCI, identifiable neurons 
around the lesion site demonstrated a staining pattern similar 
to that of control cases. (A-F, mag. ×260)
Astrocytes in the human spinal cord after traumatic injuryFigure 3
Astrocytes in the human spinal cord after traumatic 
injury. Images were taken from control spinal cords and 
cases with different survival times after SCI in transverse sec-
tions stained with the GFAP antibody. A: GFAP immunohis-
tochemistry in the unlesioned spinal cord white matter 
revealed astrocytic cell bodies (arrowheads) in between a 
homogenous network of processes. B: At 2 days after 
trauma, areas of massive tissue destruction demonstrated a 
dramatic loss of GFAP immunoreactivity. Hardly any astro-
glial cell bodies were visible and an irregular loose arrange-
ment of processes can be seen. C: 8 days after injury, highly 
GFAP-positive activated astrocytes were spread over peri-
lesional white and gray matter (arrowheads) with an 
increased density of processes. D: Eleven days after SCI, 
large, highly GFAP-positive astrocytes were surrounded by a 
dense irregular network of processes. E: In the peri-lesional 
area, about 1 segment away from the lesion site, activated 
astroglia could be detected 1 year after trauma. F: At the 
lesion site of the same case, a dense astroglial GFAP-positive 
scar was visible in which the cell bodies were hardly detecta-
ble. (A-F, mag. 215;260)Page 6 of 12
(page number not for citation purposes)
BMC Neurology 2007, 7:17 http://www.biomedcentral.com/1471-2377/7/17further away from the lesion, the number of immunoreac-
tive cells decreased rapidly; such that hardly any MMP-9
positive cell could be detected one segment distal or prox-
imal of the site of injury (Fig.5G). This distribution
remained more or less constant up to 11 day post injury.
By 24 days, large numbers of MMP-9 positive round cells
were visible at the lesion core and filled the area of tissue
destruction (Fig.5H). Double immunofluorescence
revealed these cells to be phagocytosing macrophages
(Fig.7E). At survival times of 4 months and later, only sin-
gle MMP-9 immunoreactive cells were detectable at and
around the lesion site, showing a distribution similar to
that of control cases (not shown). Apart from microglia/
macrophages and some neutrophils, no other cell popula-
tion demonstrated immunoreactivity for MMP-9 at all
time points (not shown).
Expression of MMP-12 after human SCI
In contrast to the other MMPs investigated, immunohisto-
chemistry for MMP-12 only displayed rare immunoposi-
tive, rounded cells at and around the lesion site up to 11
days post injury (Fig.5I). This distribution changed dra-
matically by 24 days, when many intensely immunoreac-
tive microglia/macrophages could be detected at the
lesion core (Fig.5J and 7F). The number of stained cells
decreased rapidly in sections further away from the lesion
such that by 1 segment proximal and distal no immuno-
reactive cells were visible. In all cases with longer survival
times, no specific MMP-12 staining was seen at and
around the lesion site (not shown).
Expression of TIMP-1, -2 and -3 after human SCI
Only rare TIMP 1, 2 or 3 immunoreactive cells could be
demonstrated at the lesion site up to 24 days post injury
(Fig. 6A, B and 6F). These cells were rounded and were
usually seen in the vicinity of blood vessels. By 4 months
and longer, no specific TIMP-1 staining could be detected
at or around the lesion site (not shown).
Immunohistochemistry for TIMP-2 demonstrated a tem-
poral loss of neuronal staining. Immunoreactivity could
be detected in most motoneurons and some interneurons
for up to 4 days (Fig.6C). However, at survival times rang-
ing from 8 to 24 days only single immunoreactive neu-
rons were visible. This was particularly evident for TIMP-
2 staining in motoneurons close to the lesion site
(Fig.6D). From 4 months, the remaining neurons dis-
played a staining pattern comparable to the control cases
with most distinguishable motoneurons being TIMP-2
positive and some positive interneurons in laminae I to VI
(not shown). Apart from intermittent immunopositive
macrophages and stained neurons, no other cell popula-
tion demonstrated TIMP-2 immunoreactivity. In contrast
to TIMP-2, the neuronal staining pattern of TIMP-3
remained unchanged over the range of survival times.
MMP-2, -9 and -12 in the human spinal cord after traumatic injuryFigure 5
MMP-2, -9 and -12 in the human spinal cord after trau-
matic injury. Images were taken from cases with different sur-
vival times after SCI in transverse sections. A: 
Immunohistochemistry for MMP-2 two days after injury. A few 
positive round cells (arrows) in areas of massive tissue destruction 
and hemorrhagic infiltration could be seen. B: In the same case, 
areas of non-haemorrhagic lesion site revealed a higher number of 
immunoreactive cells with a round to oval morphology (arrows). 
C: At 8 days after SCI, MMP-2 immunoreactive microglia/macro-
phages were still visible in areas of bleeding (arrows). D: In the 
same case, the peri-lesional area demonstrated round to oval cells 
(arrows) with a density and distribution corresponding to earlier 
survival times. E: Two days after traumatic SCI, staining for MMP-
9 demonstrated immunoreactive cells (arrows) with a mostly 
rounded morphology, in areas close to the lesion but without 
signs of hemorrhagic infiltration. F: In contrast to the more even 
distribution in E, clusters of positive cells could be seen in and 
around blood vessels (arrow). G: In sections one segment away 
from the lesion, hardly any MMP-9 positive cells were detectable. 
H: At 24 days after injury, large numbers of MMP-9 positive round 
cells were visible at the lesion epicentre, filling the area of tissue 
destruction. I: At a survival time of 2 days, immunohistochemistry 
for MMP-12 displayed rare positive cells (arrow) at the lesion site 
with a round morphology. J: At 24 days after SCI, many large 
round to oval shaped cells demonstrated strong MMP-12 immu-
noreactivity at the site of injury. (A-J, mag. ×260)Page 7 of 12
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TIMP-1, -2 and -3 in the human spinal cord after traumatic injuryFigure 6
TIMP-1, -2 and -3 in the human spinal cord after trau-
matic injury. Images were taken from cases with different 
survival times after SCI in transverse sections. A: In a section 
from patients who died 2 days after SCI, immunohistochem-
istry for TIMP-1 demonstrated occasional cells (arrow) with 
a round to oval morphology at the lesion site. B: Immunohis-
tochemistry for TIMP-2 showed an identical staining pattern, 
with single immunopositive rounded cells (arrow). C: At 4 
days post injury, identifiable motoneurons demonstrated a 
cytoplasmic TIMP-2 immunoreactivity. D: 8 days after SCI, 
only single neurons (arrow) were stained for TIMP-2 and 
many motoneurons were unstained (arrowheads). E: 8 days 
after trauma, immunohistochemistry for TIMP-3 demon-
strated cytoplasmic staining in most identifiable motoneurons 
close to the site of injury. F: In the same case, single TIMP-3 
immunoreactive round cells could be seen (arrow). G: Four 
months after SCI, gray matter of the perilesional area 
showed mostly TIMP-3 immunoreactive motoneurons. H: 
Eight months after injury, multiple activated cells (arrows, 
presumably astrocytes) were immunopositive for TIMP-3 in 
areas directly surrounding the dense glial scar. (A-H, mag. 
×260)
MMP-1, -2, -9 and -12 and TIMP-3 in macrophages and astro-cytes after traumatic human spinal cord injuryFigure 7
MMP-1, -2, -9 and -12 and TIMP-3 in macrophages 
and astrocytes after traumatic human spinal cord 
injury. Images were taken from cases with different survival 
times after SCI in transverse sections.A: 8 days after injury. 
Double immunofluorescence for CD68 (red) and MMP-1 
(green). Almost all microglia/macrophages were MMP-1 posi-
tive at the lesion site. B: 8 months after injury. Double 
immunofluorescence for GFAP (green) and MMP-1 (red). 
Large, activated, strongly GFAP-positive astrocytes express-
ing MMP-1 were observed in the glial scar tissue. C: 11 days 
after trauma, MMP-2 immunoreactivity (green) was 
expressed by CD68 positive microglia/macrophages (red) at 
the lesion site. D: 2 days after injury, CD68 positive micro-
glia/macrophages (red) were MMP-9 immunoreactive (green) 
at the lesion epicentre. E: 24 days after trauma, dense pack-
ing of large, CD68 positive macrophages (red) which also 
stained for MMP-9 (green) was visible at the lesion epicentre. 
F: In the same case, double immunofluorescence with CD68 
(red) and MMP-12 (green) showed a nearly identical distribu-
tion. G: Eight months after injury, activated GFAP-positive 
astrocytes (green) displayed TIMP-3 immunoreactivity (red) 
in the perilesional scar. (A-G, mag. ×400)
BMC Neurology 2007, 7:17 http://www.biomedcentral.com/1471-2377/7/17About half of the motoneurons were stained and single
interneurons could always be seen at and around the site
of injury (Fig.6E and 6G). Activated astrocytes became
transiently immunopositive for TIMP-3 between 8
months to 1 year after SCI (Fig.6H and 7G). Survival times
of greater than 1 year only revealed neuronal TIMP-3
immunoreactivity (not shown).
Discussion
MMPs in the CNS are largely synthesized by endothelial
cells, microglia, astrocytes and neurons under normal
conditions and can be produced at elevated levels in
response to stress [9]. A number of reports have indicated
that MMPs are involved in the pathogenesis of a wide
range of diseases and disorders of the CNS, including neu-
rodegenerative diseases such as Alzheimer's disease,
amyotrophic lateral sclerosis, Parkinson's disease and pro-
gressive supranuclear cerebral palsy [10-14] as well as
stroke injuries [15]. It has been suggested that this class of
extracellular proteases may be appropriate molecular tar-
gets to reduce secondary tissue degeneration and improve
functional outcome [7,16]. Although recent studies have
demonstrated the involvement of MMPs in experimental
models of spinal cord injury, there has, until now, been
only one recent correlative investigation regarding the
spatio-temporal distribution of MMP-9 in human spinal
cord injury [17]. In the present study, the timing and dis-
tribution of MMP-1, -2, -9 and -12, as well as their tissue
inhibitors TIMP-1, -2 and -3 were investigated in both
normal and traumatically injured samples of human spi-
nal cord. In an attempt to obtain tissue samples that were
as comparable as possible, an emphasis has been placed
on using samples obtained from cases which underwent
similar lesion type and severity. Therefore, all patients
with traumatic SCI suffered severe injuries of the macera-
tion type (for a detailed description of the morphology of
the lesion sites, see [18]) and were clinically diagnosed as
having "complete" injuries. The paucity of human speci-
mens led to the inclusion of cases from different age
groups and varying levels of injury. Thus, the present data
needs to be interpreted with care and can, by no means,
be easily generalised to patients suffering from other types
or severities of SCI. Thus, it is clear that future studies will
be needed to verify if a similar pattern of post-traumatic
MMP and TIMP expression at the lesion site can be found
in less severe- as well as other types of SCI (e.g. following
laceration and contusion type injuries). The comparison
of the present data with previous results demonstrated
that the spatio-temporal pattern of microglia/macro-
phages and astrocytic responses (i.e. the main cell popula-
tions demonstrating post traumatic MMP
immunoreactivity in the present study) supports earlier
investigations in human SCI [17].
Expression of MMPs and TIMPs in the normal CNS
In the normal, unlesioned human brain and spinal cord,
MMP and TIMP immunoreactivity was generally scarce.
The data obtained from prior investigations on the expres-
sion of MMP-1, -2 and -9 in the human nervous system
have been inconsistent, reporting either no immunoreac-
tivity [17,19-21] or MMP-1 positive microglia [20], MMP-
2 positive microglia, pericytes and blood vessels
[7,14,22,23], MMP-9 immunoreactive neurons, microglia
and single intravascular monocytes [10,22,23] and MMP-
12 immunoreactive microglia and astrocytes [24]. No
immunoreactivity for TIMP-1 and -3 has been detected.
However, TIMP-2 has been found in endothelial cells and
occasional neurons and astrocytes [20].
In the present investigation, neuronal staining for MMP-
1, TIMP-2 and -3 was detected as well as individual MMP-
9 positive intravascular monocytes. In general, the inevi-
table delays that occur before human post mortem tissues
undergo fixation will result in sub-optimal antigen preser-
vation. It therefore always remains possible that low levels
of antigen, below the level of detection by the current
immunohistochemical approach, may still be present at
pathophysiologically relevant concentrations. All mole-
cules were, nonetheless, clearly detectable in either both
control or pathological cases.
Whereas the pattern of MMP-9 immunoreactivity
observed in the present investigation supports pervious
data [17], the neuronal expression of MMP-1 has, so far,
not been reported. The expression of TIMP-2 and -3 in dif-
ferent populations of neurons, though not previously
described in human material, is in line with animal data
where both inhibitors were detected in cortical and cere-
bellar neurons [3].
The lack of immunoreactivity for MMP-2, -12 and TIMP-1
in the present control cases is unlikely to be attributable
to a lack of sensitivity, since a clear signal could be
detected in sections of traumatically injured spinal cord. It
is possible, however remote, that the earlier described
immunoreactivity in astrocytes, microglia and blood ves-
sels may reflect more activated populations of cells in the
previous control cases, despite the lack of morphological
signs of disease. In contrast to an extensive literature on
the function of MMPs and their inhibitors in pathological
situations, there is hardly any information on their func-
tion under normal conditions apart from those instances
where they have been associated with plasticity [4].
Expression of MMPs and TIMPs following human spinal 
cord injury
In the present investigation, a post-traumatic up-regula-
tion of MMP-1, -2, -9 and -12 was detected. Following
experimental SCI, several studies have reported thePage 9 of 12
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matic events at and around the lesion site. In particular,
the temporal expression pattern of almost all MMPs has
been studied after compression injury to the mouse spinal
cord [6]. An up-regulation of multiple MMPs, including
MMP-2, -9 and -12 was detected, which occurred in a
time-dependent manner, i.e. an early elevation of one
group of proteins including MMP-9 and a more delayed
elevation of others including MMP-2 and -12. In contrast
to the present investigation, MMP-1 could not be detected
in mouse spinal cord samples, at least up to 5 days after
injury [6].
The present post mortem investigation of human material
revealed a lesion-induced bi-phasic pattern of raised
MMP-1 levels at and around the lesion site. At survival
times of up to 8 days, MMP-1 was expressed in macro-
phages and microglia within the lesion epicentre, how-
ever, at the later survival times of 4 months to 1 year,
activated astrocytes at the border of the glial scar became
strongly MMP-1 immunoreactive. The delayed up-regula-
tion of MMP-1 in astrocytes in the spinal cord paren-
chyma around the lesion site might be a consequence of
earlier pro-inflammatory cytokine production since in
vitro investigations have demonstrated the release of
MMP-1 from astrocytes when stimulated by TNF-alpha or
IL-1β [25]. Furthermore, cytokines regulate the activity of
both gelatinases A and B (MMP-2 and -9) in cultured rat
astrocytes [25,26]. The early induction of MMP-1 in the
present investigation may have been associated with the
further pathological breakdown of the blood-spinal cord
barrier (see later), however, the role of the later induction
MMP-1 in reactive astroglia expression is less clear. Exper-
imental studies on wound repair after skin lesions have
demonstrated an increased expression of MMPs, includ-
ing MMP-1 in the scarless healing process of fetal injuries
[27,28]. Furthermore, an investigation into regeneration-
associated factors in the adult rat optic nerve revealed an
increased post-traumatic expression of MMP-1 in peri-
lesional astrocytes [29]. Therefore, it might be possible
that the presence of MMP-1 in the population of peri-
lesional astrocytes at the border of the evolving glial scar,
might play a role in limiting the extension of this residual
tissue barrier.
Several reports have demonstrated post-traumatic and
post-ischaemic increases in MMP-2 [6,30-32]. Increased
MMP-2 signals were detected at both protein and mRNA
levels, with elevated expression levels lasting several
weeks following experimental rat spinal cord injury [32].
A recent investigation using MMP-2 knock-out mice dem-
onstrated a more severe outcome following traumatic SCI
in mice lacking MMP-2 [8]. Knock-out mice demonstrated
a reduced white matter sparing, a more widespread reac-
tive astrogliosis as well as an impairment in spontaneous
locomotor recovery compared to wild-type littermates. In
the wild-type animals undergoing SCI, MMP-2 was
mainly expressed in astrocytes and some macrophages for
up to 2 weeks at the borders of the lesion site. In the
present human material, there was an early and brief
induction of MMP-2 in macrophages and microglia which
lasted from 2 to 8 days after injury. By 24 days, when the
first clear morphological indication of scar formation was
visible, MMP-2 expression was on the borderline of
detectability. In contrast to the situation in experimental
animals, it is likely that MMP-2 expression after human
traumatic SCI is more involved with the early vascular and
inflammatory events than with reactive astrocytosis. In
contrast to SCI, previous studies using post mortem human
tissue of multi-infarct induced dementia, ALS and Parkin-
son's disease demonstrated the expression of MMP-2 at
the border of the evolving astroglial scar or in astroglia in
the cerebral cortex or substantia nigra [12,13,30]. The cel-
lular distribution of MMP-2 expression in human pathol-
ogy therefore appears to differ significantly in relation to
the particular disease or disorder under investigation.
Contused mouse spinal cord demonstrated substantial
blood vessel wall and astrocytic MMP-9 immunoreactivity
within 3 days of injury [7]. Furthermore, the use of MMP-
9 knock-out mice following SCI demonstrated a favoura-
ble functional outcome compared to wild type animals,
with reduced blood-spinal cord barrier permeability after
the lesion and increased spared white matter [7]. In the
present study of severe traumatic SCI of the maceration
type of injury, MMP-9 was mostly expressed in macro-
phages/microglia, where levels rose progressively from 1
week to 3 weeks after injury. However, some neutrophils
were also found to be MMP-9 immunopositive at survival
times of up to 8 days after injury. Although delayed, this
spatio-temporal expression pattern is similar to that
observed in experimental investigations [6,31,32]. How-
ever, a recent investigation of human traumatic SCI, using
a heterogeneous sample of patients, found an early
increase in MMP-9 at the lesion site for up to 10 days after
injury and showed neutrophils to be the only cellular
source [17]. One possible explanation for the differences
observed between the present investigation and that of
Fleming and colleagues may be the differences in severity
and mechanism of injury for the cases chosen. Therefore,
additional studies which assess the influence of different
mechanisms of injury (e.g. maceration or laceration) on
the spatio-temporal patterns of cellular invasion and pro-
tein expression would be useful. This is of particular
importance when experimental strategies are transferred
to the clinical domain.
The up-regulation of MMP-12 following human SCI was
delayed for up to 24 days, at which time an abrupt
increase in the number of immunoreactive microglia/Page 10 of 12
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already been described as a principal source of MMP-12
[33]. The use of PCR following experimental mouse SCI
revealed that, of all MMPs induced following traumatic
injury, the induction of MMP-12 was by far the most strik-
ing, being approximately 189-fold greater than the basal
levels. Furthermore, the importance of MMP-12 expres-
sion was demonstrated by using knock-out mice, in which
an improved functional outcome was observed following
SCI. This beneficial effect was reported to be due to a
reduced permeability of the blood-spinal cord barrier and
hence reduced infiltration by neutrophils and macro-
phages, as well as a lack of direct MMP-12-induced toxic-
ity [6].
In contrast to the MMPs investigated in the present study,
the detection and distribution of their inhibitors TIMP-1,
-2 and -3 was limited. Only occasional TIMP immuno-
positive macrophages could be detected at survival times
of 2 – 24 days post injury. Neuronal TIMP-2 immunore-
activity was qualitatively reduced in comparison to con-
trol cases. The imbalance between MMPs and their
respective TIMPs in certain situations may contribute to
the development of pathology. Such an imbalance has
already been described following experimental SCI in
mice and also in the cerebral cortex of patients suffering
PSP [7,14]. The minor up-regulation of TIMPs detected in
the present study is largely in line with experimental stud-
ies using mice, in which a short term, transient up-regula-
tion of TIMP-1 was detected following spinal cord
compression injuries [6]. Therefore, similar to animal
investigations, the strong induction of multiple MMPs
after human SCI was not accompanied by a concomitant
expression of their inhibitors, allowing these proteins to
exert their effects in the lesioned spinal cord. The only
clear increase in TIMP immunoreactivity was detected for
TIMP-3 at survival times of 8 months and 1 year. In sec-
tions from these cases, the same peri-lesional activated
astrocytes which expressed MMP-1 were also immunore-
active for TIMP-3. It may be that the up-regulation of
TIMP-3 acts to limit the effects of MMP-1, but this sugges-
tion remains speculative.
Conclusion
The involvement of MMP-1, -2, -9 and -12 has been dem-
onstrated in the post-traumatic events after human SCI.
This investigation comprised of 15 patients who died at a
range of different survival times after trauma. Due to the
difficulties in obtaining post mortem human tissue speci-
mens, only one case could be studied at each survival
time. Although cases with similar survival times demon-
strated similar immunohistochemical staining patterns,
the present results need to be interpreted with caution,
and further studies with more human cases per survival
time would be of significant value.
All 4 MMPs were mainly expressed during the first weeks
after injury and are most likely involved in the destructive
inflammatory events of protein breakdown and phagocy-
tosis by infiltrating neutrophils and macrophages as well
as enhanced permeability of the blood-spinal cord barrier.
Their temporal expression pattern corresponds largely to
prior experimental studies, several of which have indi-
cated that inhibition of MMPs may lead to improved func-
tional outcomes. However, the lack of any clear indication
of the exact functional role (beneficial or detrimental) of
many MMPs in human spinal cord, plus the lack of spe-
cific inhibitors suggests that more research on this issue is
warranted. Nonetheless, the present data on the spatio-
temporal expression of MMPs and TIMPs following
human SCI has demonstrated that experimental animal
models do not always accurately predict the timing and
expression pattern of key molecules in the clinical situa-
tion, and that such correlative investigations are impor-
tant for the logical extension of drug development from
the laboratory to the clinic.
Abbreviations
Blood Spinal Cord barrier – BSB
Central nervous system – CNS
Extracellular matrix – ECM
Glial fibrillary acidic protein – GFAP
Matrix Metalloproteinase – MMP
Spinal cord injury – SCI
Tissue inhibitors of metalloproteinases – TIMP
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
AB designed and coordinated the study and drafted the
manuscript. KP carried out the immunohistochemical
stainings. BK participated in the design of the study, pro-
vided specimens and helped to draft the manuscript. DM
participated in the design of the study, provided speci-
mens and helped to draft the manuscript. JS participated
in the design of the study, provided specimens and helped
to draft the manuscript. JN participated in the design of
the study and helped to draft the manuscript. GB partici-
pated in the design and coordination of the study and
helped to draft the manuscript. All authors read and
approved the final manuscript.Page 11 of 12
(page number not for citation purposes)
BMC Neurology 2007, 7:17 http://www.biomedcentral.com/1471-2377/7/17Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Acknowledgements
The authors thank S. Lecouturier for excellent technical assistance. This 
work was supported by a grant from the Deutsche Stiftung Querschnitt-
slähmung (DSQ).
References
1. Schwab ME, Bartholdi D: Degeneration and regeneration of
axons in the lesioned spinal cord.  Physiol Rev 1996, 76:319-70.
2. Sternlicht MD, Werb Z: How matrix metalloproteinases regu-
late cell behavior.  Annu Rev Cell Dev Biol 2001, 17:463-516.
3. Dzwonek J, Rylski M, Kaczmarek L: Matrix metalloproteinases
and their endogenous inhibitors in neuronal physiology of
the adult brain.  FEBS Lett 2004, 567:129-35.
4. Yong VW, Power C, Forsyth P, Edwards DR: Metalloproteinases
in biology and pathology of the nervous system.  Nat Rev Neu-
rosci 2001, 2:502-11.
5. Yong VW: Metalloproteinases: mediators of pathology and
regeneration in the CNS.  Nat Rev Neurosci 2005, 6:931-944.
6. Wells JE, Rice TK, Nuttall RK, Edwards DR, Zekki H, Rivest S, Yong
VW: An adverse role for matrix metalloproteinase 12 after
spinal cord injury in mice.  J Neurosci 2003, 23:10107-15.
7. Noble LJ, Donovan F, Igarashi T, Goussev S, Werb Z: Matrix met-
alloproteinases limit functional recovery after spinal cord
injury by modulation of early vascular events.  J Neurosci 2002,
22:7526-35.
8. Hsu JY, McKeon R, Goussev S, Werb Z, Lee JU, Trivedi A, Noble-
Haeusslein LJ: Matrix metalloproteinase-2 facilitates wound
healing events that promote functional recovery after spinal
cord injury.  J Neurosci 2006, 26:9841-9850.
9. Rosenberg GA: Matrix metalloproteinases in neuroinflamma-
tion.  Glia 2002, 39:279-291.
10. Asahina M, Yoshiyama Y, Hattori T: Expression of matrix metal-
loproteinase-9 and urinary-type plasminogen activator in
Alzheimer's disease brain.  Clin Neuropathol 2001, 20:60-63.
11. Backstrom JR, Miller CA, Tokes ZA: Characterization of neutral
proteinases from Alzheimer-affected and control brain spec-
imens: identification of calcium-dependent metalloprotein-
ases from the hippocampus.  J Neurochem 1992, 58:983-992.
12. Lim GP, Backstrom JR, Cullen MJ, Miller CA, Atkinson RD, Tokes ZA:
Matrix metalloproteinases in the neocortex and spinal cord
of amyotrophic lateral sclerosis patients.  J Neurochem 1996,
67:251-259.
13. Lorenzl S, Albers DS, Narr S, Chirichigno J, Beal MF: Expression of
MMP-2, MMP-9, and MMP-1 and their endogenous counter-
regulators TIMP-1 and TIMP-2 in postmortem brain tissue of
Parkinson's disease.  Exp Neurol 2002, 178:13-20.
14. Lorenzl S, Albers DS, Chirichigno JW, Augood SJ, Beal MF: Elevated
levels of matrix metalloproteinases-9 and -1 and of tissue
inhibitors of MMPs, TIMP-1 and TIMP-2 in postmortem
brain tissue of progressive supranuclear palsy.  J Neurol Sci
2004, 218:39-45.
15. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR:
Increased gelatinase A (MMP-2) and gelatinase B (MMP-9)
activities in human brain after focal ischemia.  Neurosci Lett
1997, 238:53-56.
16. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC: Matrix
metalloproteinase expression increases after cerebral focal
ischemia in rats: inhibition of matrix metalloproteinase-9
reduces infarct size.  Stroke 1998, 29:1020-1030.
17. Fleming JC, Norenberg MD, Ramsay DA, Dekaban GA, Marcillo AE,
Saenz AD, Pasquale-Styles M, Dietrich WD, Weaver LC: The cellu-
lar inflammatory response in human spinal cords after
injury.  Brain 2006.
18. Buss A, Pech K, Kakulas BA, Martin D, Schoenen J, Noth J, Brook GA:
Growth-modulating molecules are associated with invading
Schwann cells and not astrocytes in human traumatic spinal
cord injury.  Brain 2007, epub ahead of print:.
19. Cossins JA, Clements JM, Ford J, Miller KM, Pigott R, Vos W, van der
Valk P, de Groot CJ: Enhanced expression of MMP-7 and MMP-
9 in demyelinating multiple sclerosis lesions.  Acta Neuropathol
(Berl) 1997, 94:590-8.
20. Lampert K, Machein U, Machein MR, Conca W, Peter HH, Volk B:
Expression of matrix metalloproteinases and their tissue
inhibitors in human brain tumors.  Am J Pathol 1998, 153:429-37.
21. Nakagawa T, Kubota T, Kabuto M, Sato K, Kawano H, Hayakawa T,
Okada Y: Production of matrix metalloproteinases and tissue
inhibitor of metalloproteinases-1 by human brain tumors.  J
Neurosurg 1994, 81:69-77.
22. Maeda A, Sobel RA: Matrix metalloproteinases in the normal
human central nervous system, microglial nodules, and mul-
tiple sclerosis lesions.  J Neuropathol Exp Neurol 1996, 55:300-9.
23. Rosenberg GA, Sullivan N, Esiri MM: White matter damage is
associated with matrix metalloproteinases in vascular
dementia.  Stroke 2001, 32:1162-8.
24. Vos CM, van Haastert ES, de Groot CJ, van der Valk P, de Vries HE:
Matrix metalloproteinase-12 is expressed in phagocytotic
macrophages in active multiple sclerosis lesions.  J Neuroimmu-
nol 2003, 138:106-14.
25. Gottschall PE, Yu X: Cytokines regulate gelatinase A and B
(matrix metalloproteinase 2 and 9) activity in cultured rat
astrocytes.  J Neurochem 1995, 64:1513-1520.
26. Vos CM, Sjulson L, Nath A, McArthur JC, Pardo CA, Rothstein J,
Conant K: Cytotoxicity by matrix metalloprotease-1 in orga-
notypic spinal cord and dissociated neuronal cultures.  Exp
Neurol 2000, 163:324-330.
27. Dang CM, Beanes SR, Lee H, Zhang X, Soo C, Ting K: Scarless fetal
wounds are associated with an increased matrix metallopro-
teinase-to-tissue-derived inhibitor of metalloproteinase
ratio.  Plast Reconstr Surg 2003, 111:2273-85.
28. Peled ZM, Phelps ED, Updike DL, Chang J, Krummel TM, Howard
EW, Longaker MT: Matrix metalloproteinases and the ontog-
eny of scarless repair: the other side of the wound healing
balance.  Plast Reconstr Surg 2002, 110:801-11.
29. Ahmed Z, Dent RG, Leadbeater WE, Smith C, Berry M, Logan A:
Matrix metalloproteases: degradation of the inhibitory envi-
ronment of the transected optic nerve and the scar by regen-
erating axons.  Mol Cell Neurosci 2005, 28:64-78.
30. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry
VH: Differential matrix metalloproteinase expression in
cases of multiple sclerosis and stroke.  Neuropathol Appl Neuro-
biol 1997, 23:406-415.
31. de Castro RC Jr., Burns CL, McAdoo DJ, Romanic AM: Metallopro-
teinase increases in the injured rat spinal cord.  Neuroreport
2000, 11:3551-4.
32. Duchossoy Y, Horvat JC, Stettler O: MMP-related gelatinase
activity is strongly induced in scar tissue of injured adult spi-
nal cord and forms pathways for ingrowing neurites.  Mol Cell
Neurosci 2001, 17:945-56.
33. Shapiro SD, Kobayashi DK, Ley TJ: Cloning and characterization
of a unique elastolytic metalloproteinase produced by
human alveolar macrophages.  J Biol Chem 1993, 268:23824-9.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2377/7/17/prepubPage 12 of 12
(page number not for citation purposes)
